Exploiting Polypharmacology in Precision Oncology: Identification of Differential Kinase Off-targets Among Clinical PARP Inhibitors
Poster Nov 08, 2017
Dr. Albert A. Antolin, Dr. Jordi Mestres, Prof. Paul Workman and Dr. Bissan Al-Lazikani
A more comprehensive and systems-based approach to pharmacology is uncovering that drugs tend to bind to more than one target, a behaviour commonly referred to as polypharmacology with clinical implications that are still not well understood.1
The increasing availability of ligand-target interaction data in the public domain in resources such as canSAR2 enables the development of computational methods to predict polypharmacology, that are becoming a cost-effective means to uncover new targets of drugs. PARP inhibitors are a new class of targeted small-molecule cancer therapeutics that have shown unexplained differential effects in cellular models and clinical trials.3
Can we use computational methods to identify previously unknown off-targets of PARP inhibitors that can explain their observed differences?
(1) Jalencas X, Mestres J. On the origins of drug polypharmacology. Med. Chem. Commun.,4, 80-87 (2013).
(2) Tym JE, Mitsopoulos C, Coker EA, Razaz P, Schierz AC, Antolin AA, Al-Lazikani B. CanSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Res. 44, D938-43 (2016).
(3) Antolín AA, Mestres J. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget. 5, 3023-8 (2014).
T-helper cell phenotype expression in cutaneous lesions of angioimmunoblastic T-cell lymphomaPoster
Angioimmunoblastic T-cell lymphoma (AITL) is a common type of peripheral T-cell lymphoma. AITL can be missed until lymphadenopathy develops in patients initially presenting with skin lesions, as skin biopsy may lack conclusive findings. Our case highlights the extranodal presentation of AITL with cutaneous lesions displaying the TFH phenotype.READ MORE
Novel Role of the Innate Immune DNA Sensor IFI16 (Interferon Gamma Inducible Protein 16) as a Major Epigenetic Modulator During KSHV Infection and Lytic ReactivationPoster
Studies have shown that IFI16 acts as an antiviral restriction factor against a number of DNA viruses, by inhibiting viral replication or transcription through epigenetic modifications. However, till date, no specific epigenetic function of IFI16 has been identified. Here, we have discovered that IFI16 recruits two histone methyltransferases on the KSHV episome leading to altered Histone H3K9 methylation, thus regulating its lifecycle.READ MORE
Liver Transplantation for Hepatocellular Carcinoma Outperform Other Populations in the New Hepatitis C EraPoster
Long term results of HCC liver transplants (LTx) in the recent era of direct-acting antivirals (DAA) against hepatitis C (HCV) are not available. We aimed to examine the access, treatments and cure rates with DAA’s utilized in HCC LTx with HCV. Secondarily, we aimed to determine the long term impact of the Liver Cancer Program and DAA therapies on survival of HCC LTx.READ MORE